Journal
PHARMACEUTICAL PATENT ANALYST
Volume 7, Issue 5, Pages 193-227Publisher
FUTURE SCI LTD
DOI: 10.4155/ppa-2018-0016
Keywords
Ga-68; gallium-68; PET radiotracers; radiochemistry; radiotherapy; theragnostics
Categories
Funding
- US Department of Energy (DOE) [DE-SC0012484]
- University of Michigan (College of Pharmacy, Rackham Graduate School)
- NIH
- US DOE
- Alzheimer's Association
- Avid Radiopharmaceuticals/Eli Lilly
- Bristol-Myers Squibb
- Merck
- Adeptio
- GE Healthcare
- AbbVie
- Ionetix
Ask authors/readers for more resources
Commercial Ge-68/Ga-68 generators provide a means to produce positron emission tomography agents on site without use of a cyclotron. This development has led to a rapid growth of academic literature and patents ongallium-68 (Ga-68). As Ga-68 positron emission tomography agents usually involve a targeting moiety attached to a metal chelator, the development lends itself to the investigation of theragnostic applications; the Ga-68-based diagnostic is utilized to determine if the biological target is present and, if so, a therapeutic isotope (e.g., Lu-177, Ac-225) can be complexed with the same scaffold to generate a corresponding radiotherapeutic. This review considers patents issued between 2012 and 2017 that contain a Ga-68-labeled molecule indexed by Chemical Abstract Services (a division of the American Chemical Society).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available